Rhythm Biosciences offers high-upside colorectal cancer diagnostics exposure, but the re-rating depends on turning promising IP into reimbursed, high-volume clinical testing.
Overview
Rhythm Biosciences is shifting from oncology R&D to commercial diagnostics, using an in-house Melbourne laboratory model to sell blood-based colorectal cancer testing on a per-test basis. Its ColoSTAT® proteomic test targets active disease triage, while acquired geneType™ adds lifetime genetic risk prediction. The opportunity is large because bowel cancer screening participation remains low and stool-test compliance is poor. Commercial success hinges on scaling test volumes, securing reimbursement, and proving clinical utility through domestic and international partnerships.